Delta-9-tetrahydrocannabinol + cannabidiol. A reasonable option for some patients with multiple sclerosis

Delta-9-tetrahydrocannabinol + cannabidiol. A reasonable option for some patients with multiple sclerosis.

“Conventional drugs have only a limited impact on spasticity associated with multiple sclerosis and are rarely satisfactory. A solution for oral transmucosal delivery (spray) containing a mixture of cannabis extracts (2.7 mg of delta-9-tetrahydrocannabinol + 2.5 mg of cannabidiol per spray) has been granted marketing authorisation in France for patients who are inadequately relieved by standard treatments.

Read more
Add your reaction Share

Advances in the Management of MS Spasticity: Recent Observational Studies

Advances in the Management of MS Spasticity: Recent Observational Studies.

“Clinical trials demonstrate the efficacy and tolerability of an intervention under experimental conditions, but information on use under daily practice conditions is required to confirm the effectiveness and safety of new management options.

Read more
Add your reaction Share

Evaluation of the tolerability and efficacy of Sativex in multiple sclerosis

Evaluation of the tolerability and efficacy of Sativex in multiple sclerosis.

“Refractory spasticity, central neuropathic pain and bladder dysfunction are common clinical problems in patients with multiple sclerosis (MS). None of the currently available oral medications has proven to be reliably effective and can be limited by toxicity.

Read more
Add your reaction Share

There is evidence for the use of cannabinoids for symptomatic treatment of multiple sclerosis

There is evidence for the use of cannabinoids for symptomatic treatment of multiple sclerosis.

“We identified 16 randomized placebo-controlled trials investigating cannabinoids as symptomatic treatment in multiple sclerosis (MS).

Read more
Add your reaction Share